Oligometastatic upper gastrointestinal (UGI) cancers represent a biologically distinct state in which aggressive local therapies can lead to prolonged survival or even, in selected cases, durable remission. This concept has received increasing attention as growing evidence supports the integration of surgery or other local approaches alongside systemic treatment in patients with a limited metastatic burden.

In oesophageal cancer, clinical investigations have primarily focused on metachronous recurrences. Retrospective studies and case series suggest a survival benefit in patients with a long disease-free interval, a favorable response to systemic therapy, and the possibility of achieving complete tumor resection with low operative risk. Within this context, pulmonary and cervical lymph node oligometastases have emerged as ideal candidates for local treatment, given their resectability and the relatively limited morbidity associated with surgery in these locations.

In gastric cancer, most available studies, both retrospective and prospective, suggest that surgery may be a valuable therapeutic option in selected patients with synchronous oligometastatic disease, where both primary and metastatic lesions are treated during the same procedure. However, the only randomised trial to date, FLOT5/RENAISSANCE, provides inconclusive results that do not allow for definitive recommendations.

While these findings do not yet support a full-scale surgical renaissance, they reinforce the legitimate and increasingly recognised role of surgery as part of a multimodal treatment approach for both gastric and oesophageal cancers. The integration of systemic and local therapies, guided by multidisciplinary evaluation and tumor biology, holds the promise of extending therapeutic objectives beyond palliation toward sustained disease control in carefully selected patients.